179 related articles for article (PubMed ID: 6508821)
41. Regulatory kinetics of wheat-germ aspartate transcarbamoylase. Adaptation of the concerted model to account for complex kinetic effects of uridine 5'-monophosphate.
Yon RJ
Biochem J; 1984 Jul; 221(2):281-7. PubMed ID: 6477473
[TBL] [Abstract][Full Text] [Related]
42. Complex of N-phosphonacetyl-L-aspartate with aspartate carbamoyltransferase. X-ray refinement, analysis of conformational changes and catalytic and allosteric mechanisms.
Ke HM; Lipscomb WN; Cho YJ; Honzatko RB
J Mol Biol; 1988 Dec; 204(3):725-47. PubMed ID: 3066911
[TBL] [Abstract][Full Text] [Related]
43. In situ properties of Helicobacter pylori aspartate carbamoyltransferase.
Burns BP; Mendz GL; Hazell SL
Arch Biochem Biophys; 1997 Nov; 347(1):119-25. PubMed ID: 9344472
[TBL] [Abstract][Full Text] [Related]
44. Peptide-protein interaction markedly alters the functional properties of the catalytic subunit of aspartate transcarbamoylase.
Zhou BB; Schachman HK
Protein Sci; 1993 Jan; 2(1):103-12. PubMed ID: 8443583
[TBL] [Abstract][Full Text] [Related]
45. T-state inhibitors of E. coli aspartate transcarbamoylase that prevent the allosteric transition.
Heng S; Stieglitz KA; Eldo J; Xia J; Cardia JP; Kantrowitz ER
Biochemistry; 2006 Aug; 45(33):10062-71. PubMed ID: 16906764
[TBL] [Abstract][Full Text] [Related]
46. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor.
Stewart DJ; Leavens M; Friedman J; Benjamin RS; Moore EC; Bodey GP; Valdivieso M; Burgess MA; Wiseman C; Loo TL
Cancer Res; 1980 Sep; 40(9):3163-6. PubMed ID: 7427934
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
Leyva A; Appel H; Smith P; Lankelma J; Pinedo HM
Cancer Lett; 1981 Mar; 12(1-2):169-73. PubMed ID: 7273001
[TBL] [Abstract][Full Text] [Related]
48. The allosteric activator Mg-ATP modifies the quaternary structure of the R-state of Escherichia coli aspartate transcarbamylase without altering the T<-->R equilibrium.
Fetler L; Vachette P
J Mol Biol; 2001 Jun; 309(3):817-32. PubMed ID: 11397099
[TBL] [Abstract][Full Text] [Related]
49. Properties of single-step mutants of Syrian hamster cell lines resistant to N-(phosphonacetyl)-L-aspartate.
Zieg J; Clayton CE; Ardeshir F; Giulotto E; Swyryd EA; Stark GR
Mol Cell Biol; 1983 Nov; 3(11):2089-98. PubMed ID: 6656764
[TBL] [Abstract][Full Text] [Related]
50. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
Kensler TW; Jayaram HN; Cooney DA
Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
[TBL] [Abstract][Full Text] [Related]
51. The effects of pH and inhibitors upon the catalytic activity of the dihydroorotase of multienzymatic protein pyr1-3 from mouse Ehrlich ascites carcinoma.
Christopherson RI; Jones ME
J Biol Chem; 1980 Apr; 255(8):3358-70. PubMed ID: 6102565
[TBL] [Abstract][Full Text] [Related]
52. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
Friedman J; Moore EC; Hall SW; Loo TL
Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
[TBL] [Abstract][Full Text] [Related]
53. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
Grant S; Rauscher F; Jakubowski A; Cadman E
Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
[TBL] [Abstract][Full Text] [Related]
54. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
Moyer JD; Smith PA; Levy EJ; Handschumacher RE
Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293
[TBL] [Abstract][Full Text] [Related]
55. Evidence from 13C NMR for protonation of carbamyl-P and N-(phosphonacetyl)-L-aspartate in the active site of aspartate transcarbamylase.
Roberts MF; Opella SJ; Schaffer MH; Phillips HM; Stark GR
J Biol Chem; 1976 Oct; 251(19):5976-85. PubMed ID: 9410
[TBL] [Abstract][Full Text] [Related]
56. Structural consequences of the replacement of Glu239 by Gln in the catalytic chain of Escherichia coli aspartate transcarbamylase.
Tauc P; Vachette P; Middleton SA; Kantrowitz ER
J Mol Biol; 1990 Jul; 214(1):327-35. PubMed ID: 1973463
[TBL] [Abstract][Full Text] [Related]
57. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
Chan TC; Howell SB
Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
[TBL] [Abstract][Full Text] [Related]
58. Phase I and clinical pharmacological evaluation of biochemical modulation of 5-fluorouracil with N-(phosphonacetyl)-L-aspartic acid.
Casper ES; Vale K; Williams LJ; Martin DS; Young CW
Cancer Res; 1983 May; 43(5):2324-9. PubMed ID: 6831457
[TBL] [Abstract][Full Text] [Related]
59. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Erlichman C
Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
[TBL] [Abstract][Full Text] [Related]
60. N-(Phosphonacetyl)-L-aspartate (PALA): current status.
Rozencweig M; Abele R; Piccart M; Von Hoff DD; Muggia FM
Recent Results Cancer Res; 1980; 74():72-7. PubMed ID: 7444151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
